Fig. 2.
18F-FDG PET/CT images of patient nine who developed a permanent hypothyroidism. Images a were performed at baseline. Images b, c were, respectively, obtained 3 and 5 months after the beginning of nivolumab associated with ipilimumab, and revealed a diffusely increased thyroid uptake. Three months after the end of immune checkpoint inhibitors, images d showed a complete regression of the previously increased thyroid uptake and a significant decrease of thyroid volume on CT